Skip to main content

Vivos Inc.

corporate_fare Company Profile

Vivos Inc.

RDGL·OTC·Industrial Applications And Services·CIK 0001449349

Vivos Inc. is a radiation oncology medical device company that develops yttrium-90 (Y-90) based precision radionuclide therapy devices. These include RadioGel® Precision Radionuclide Therapy™ for treating solid tumors and positive surgical margins in humans, and IsoPet® for treating solid tumors in animals. The company also sells PLGA-g-PEG polymers and PrecisionGel™, a hydrogel polymer platform designed for delivering active pharmaceutical ingredients and therapeutic agents. Its development efforts are led by a team of radiochemists, scientists, and engineers, working with strategic partners such as national laboratories, universities, and private corporations. In 2013, the United States Food and Drug Administration (FDA) determined that RadioGel® is a device for human therapy for non-resectable cancers. In January 2018, the Center for Veterinary Medicine Product Classification Group classified RadioGel® (now IsoPet® for veterinary use) as a medical device for animal therapy, initially specified for feline sarcomas and canine soft tissue sarcomas. The company believes this classification may extend to a broader range of veterinary cancers, including most solid tumors in animals. As veterinary medical devices do not require premarket approval or notification for commercial distribution in the United States, IsoPet® is authorized for marketing and commercial distribution following this classification, provided it is safe, effective, properly labeled, and compliant with applicable laws and regulations.

Vivos Inc. (OTC:RDGL) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 12 items for RDGL at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 8/10. Across its 12 most recent items scored 7 or higher, the top rating is 9/10, with 6 rated 8 or above. Recent SEC coverage for RDGL spans 10-Q, DEF 14A, 8-K, 4.

Recent high-impact activity:

  • Vivos Q3 2026: $2.75M Nine-Month Loss, Going Concern Doubt, $1.8M Cash
  • Vivos Seeks 102.8M-Share Equity Plan (20% of Shares) at December 9 Annual Meeting
  • Vivos Raises $1M in Reg A+ Sale, Issues 25M Warrants and Swaps 8M Warrants for Stock
  • Director Carl Cadwell Injects $250K Cash and Converts Series C to Series D Preferred
  • Vivos Creates Series D Convertible Preferred with $0.08 Conversion Price and 50x Voting Rights

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$68.38K
Net Income
-$3.07M
Diluted EPS
-$0.01
Op. Cash Flow
-$2.06M
Free Cash Flow
-$2.16M
Gross Profit
-$59.76K
Operating Income
-$3.17M
Cash & Equivalents
$1.56M
Debt / Equity
0.00×
Net Margin
-44.84×
Shares Outstanding
455.49M sh
Source: 10-K · filed 2026-03-30 · accession 0001493152-26-013701

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 124,174 shares in RDGL as of the October 30, 2026 settlement, a 3213.1% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 27.9% of RDGL volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)124,174 shares as of October 30, 2026
Change vs prior period▲ 3213.1%
Days to cover1.00 at avg daily volume of 1,427,500
Daily short volume (FINRA facilities)27.9% of 3,381,573 shares on November 20, 2026
5-day average short volume36.7%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for RDGL, detected from its recent SEC filings · based on capital-structure filings through 2026-11-05.

Reg A+ Share Sale Raises $1 Million · 25 Million Warrants Sold for $25,000

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with R →
$0.0352 -14.36% today
52-week range · as of 2026-11-12 $0.0352 – $0.1244
Market cap
$19.79M
Volume
4M (5.7× avg)
3-mo avg 701.5K
Live data · 2026-11-22 12:25 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed RDGL - Latest Insights

RDGL
Nov 12, 2026, 4:25 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.044
Real-time Price: $0.0352 info
Change: -$0.0088 (-20%) info
Market Cap: $19.79M info
RDGL
Nov 09, 2026, 4:31 PM EST
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $0.0428
Real-time Price: $0.0352 info
Change: -$0.0076 (-18%) info
Market Cap: $19.79M info
RDGL
Nov 05, 2026, 8:54 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.042
Real-time Price: $0.0352 info
Change: -$0.0068 (-16%) info
Market Cap: $19.79M info
RDGL
Oct 08, 2026, 4:46 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.045885
Real-time Price: $0.0352 info
Change: -$0.010685 (-23%) info
Market Cap: $19.79M info
RDGL
Oct 05, 2026, 5:26 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.0431
Real-time Price: $0.0352 info
Change: -$0.0079 (-18%) info
Market Cap: $19.79M info
RDGL
Oct 01, 2026, 5:15 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $0.04981
Real-time Price: $0.0352 info
Change: -$0.01461 (-29%) info
Market Cap: $19.79M info
RDGL
Aug 18, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.05735
Real-time Price: $0.0352 info
Change: -$0.02215 (-39%) info
Market Cap: $19.79M info
RDGL
Aug 12, 2026, 4:33 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.0547
Real-time Price: $0.0352 info
Change: -$0.0195 (-36%) info
Market Cap: $19.79M info
RDGL
Jul 06, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $0.057235
Real-time Price: $0.0352 info
Change: -$0.022035 (-38%) info
Market Cap: $19.79M info
RDGL
May 14, 2026, 4:52 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $0.0678
Real-time Price: $0.0352 info
Change: -$0.0326 (-48%) info
Market Cap: $19.79M info
RDGL
May 14, 2026, 4:45 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.0678
Real-time Price: $0.0352 info
Change: -$0.0326 (-48%) info
Market Cap: $19.79M info
RDGL
Mar 30, 2026, 7:13 PM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $0.0899
Real-time Price: $0.0352 info
Change: -$0.0547 (-61%) info
Market Cap: $19.79M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets